Emilien BILLON

Mr. Emilien BILLON


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
EBEmilien BILLON
Emilien BILLON
JWJochen Walz
Jochen Walz
SBSerge Brunelle
Serge Brunelle
JTJeanne Thomassin
Jeanne Thomassin
NSNaji Salem
Naji Salem
GGGwenaëlle Gravis
Gwenaëlle Gravis
Background: Renal cell carcinoma is the third most prevalent urological cancer worldwide and about 30% of patients present with metastatic disease at the time of diagnosis. Systemic treatments for metastatic renal cell carcinoma have improved recently. Vascular endothelial growth factor targeting therapies were the previous standard of care. However, immune checkpoint inhibitors used in second line therapy have now been shown to improve patient survival. We report a case of metastatic renal cell carcinoma with nivolumab as a second-line therapy after progression with tyrosine kinase inhibitor therapy. Unusual adverse events in metastatic renal cell carcinoma, such as vitiligo, were observed in this patient who developed a remarkable documented pathological complete response to his renal tumor. Case presentation: A 60-year-old caucasian male was diagnosed with a pulmonary metastatic clear cell renal cell carcinoma. Sunitinib was used as first line treatment without success. He received nivolumab in second-line treatment. He developed several immune-related adverse events, most notably vitiligo. The patient had a radiological complete response on metastatic sites, with a significant decrease of renal tumor volume and underwent cytoreductive nephrectomy after 2 years of treatment, confirming the pathological complete response. The patient remains disease-free for 10 months without further systemic therapy after nivolumab discontinuation. Conclusions: Pathological complete response with nivolumab in metastatic renal cell carcinoma is rare. This case further highlights the potentially predictive role of immune-related adverse events during nivolumab therapy for metastatic renal cell carcinoma and raises questions concerning the role of nephrectomy after immune checkpoint inhibitor therapy. Further studies are needed to better identify predictive factors for treatment response to immunotherapy in metastatic renal cell carcinoma, and to better understand the role of nephrectomy after nivolumab treatment.

3 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EBEmilien BILLON
Emilien BILLON
GGGwenaelle Gravis
Gwenaelle Gravis
AGArnaud Guille
Arnaud Guille
NCNadine Carbuccia
Nadine Carbuccia
JAJose Adelaide
Jose Adelaide
FBFrançois Bertucci
François Bertucci
Introduction. The prognosis of advanced urological cancers (AUC) remains unfavorable, and few data are available regarding precision medicine. Methods: the PERMED-01 prospective clinical trial assessed the impact of molecular profiling in adults with refractory advanced solid cancer, in terms of number of patients with tumor actionable genetic alterations (AGA), feasibility, description of molecular alterations, treatment, and clinical outcome. We present here those results in the 64 patients enrolled with AUC. DNA extracted from a new tumor biopsy was profiled in real-time (targeted NGS, whole-genome array-comparative genomic hybridization), and the results were discussed during a weekly molecular tumor board meeting. Results: a complete molecular profile was obtained in 49 patients (77%). Thirty-eight (59%) had at least one AGA. Twelve (19%) received a matched therapy on progression, of which 42% had a PFS2/PFS1 ratio ≥ 1.3 versus 5% in the “non-matched therapy group” (n = 25). The objective response and disease control rates were higher in the “matched therapy group” (33% and 58%, respectively) than in the “non-matched therapy group” (13% and 22%), as was the 6-month OS (75% vs. 42%). Conclusion: the profiling of a newly biopsied tumor sample identified AGA in 59% of patients with AUC, led to “matched therapy” in 19%, and provided clinical benefit in 8%.

7 October 2023 in European Urology Oncology
Verified
Journal Article
Closed access
EBEmilien BILLON
Emilien BILLON
CDCécile Dalban
Cécile Dalban
SOStephane Oudard
Stephane Oudard
CCChristine Chevreau
Christine Chevreau
BLBrigitte Laguerre
Brigitte Laguerre
GGGwenaelle Gravis
Gwenaelle Gravis

1 April 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
EBEmilien BILLON
Emilien BILLON
LTLouis Tassy
Louis Tassy
MSMatthieu Sarabi
Matthieu Sarabi
CBCécile Braticevic
Cécile Braticevic
MCMaud Cecile
Maud Cecile
FRFrédérique Rousseau
Frédérique Rousseau

1 November 2021 in Bulletin du Cancer
Verified
Journal Article
Closed access
EBEmilien BILLON
Emilien BILLON
LTLouis Tassy
Louis Tassy
OBOphélie Boulogne
Ophélie Boulogne
MCMaud Cecile
Maud Cecile
CBCécile Braticevic
Cécile Braticevic
FRFrédérique Rousseau
Frédérique Rousseau